<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB

(Mark one)

 x       Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities
---      Exchange Act of 1934

         For the Quarter Period Ended November 30, 1999

__       Transition Report Pursuant to Section 13 or 15(d) of the Securities
         Exchange Act of 1934 for the transition period from _______ to _______.

                                                     Commission File No. 0-26189
                                                                         -------

                        ALLERGY IMMUNO TECHNOLOGIES, INC.
--------------------------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)



Delaware                                                     95-3937129
--------------------------------------------------------------------------------
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                               Identification No.)



1531 Monrovia Avenue, Newport Beach, California               92663
--------------------------------------------------------------------------------
(Address of principal executive offices)                      (Zip Code)


Registrant's telephone number including area code:  (949) 645-3703
--------------------------------------------------------------------------------


                                (Not applicable)
--------------------------------------------------------------------------------
   (Former name, former address and former fiscal year, if changed since last
                                    report.)


Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.


                                  Yes  X     No
                                      ---       ---

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: 17,170,390 shares of Common
Stock as of January 5, 2000.



<PAGE>


                        ALLERGY IMMUNO TECHNOLOGIES, INC.

                                      INDEX

                          PART I FINANCIAL INFORMATION

ITEM 1.   Financial Statements:


          Statements of Operations (unaudited) - Six Months and Three Months
          Ended November 30, 1999 and 1998.....................................2


          Balance Sheet (unaudited) - November 30, 1999....................3 & 4


          Statements of Cash Flows (unaudited)
          Six Months Ended November 30, 1999 and 1998..........................5


          Statement of Changes in Shareholders' Deficit (unaudited) -
          Six Months Ended November 30, 1999...................................6


          Notes to Financial Statements......................................7-9


ITEM 2.   Management's Discussion and Analysis of Financial Condition
          and Selected Financial Data.........................................10


                            PART II OTHER INFORMATION


          Signatures..........................................................11


                                       i

<PAGE>
<TABLE>

                                               PART I - FINANCIAL INFORMATION
                                              SUMMARIZED FINANCIAL INFORMATION

                                              ALLERGY IMMUNO TECHNOLOGIES, INC.
                                             STATEMENTS OF OPERATIONS (UNAUDITED)

<CAPTION>

                                                                      Six Months Ended                  Three Months Ended
                                                                        November 30,                       November 30,
                                                                 1999               1998               1999               1998
                                                              ----------         ----------         ----------         ----------
<S>                                                           <C>                <C>                <C>                <C>
Net sales...................................................  $  43,591          $  38,195          $  18,692          $  15,048

     Cost of sales..........................................     42,057             42,790             18,884             22,995
                                                              ----------         ----------         ----------         ----------
     Gross profit (loss)....................................      1,534             (4,595)              (192)            (7,947)

Operating
     Selling, general and administrative....................     97,011             31,931             37,307             17,551
     Research and development...............................          0                300                  0                150
                                                              ----------         ----------         ----------         ----------
Total operating expenses....................................     97,011             32,231             37,307             17,701

Operating...................................................    (95,477)           (36,826)          (37,499)            (25,648)

Other
     Other income, net......................................       (594)              (883)              (330)              (839)
                                                              ----------         ----------         ----------         ----------

(Loss) income before taxes..................................    (94,883)           (35,943)           (37,169)           (24,809)

Income Taxes................................................        800                800                  0                  0
                                                              ----------         ----------         ----------         ----------
NET (LOSS) INCOME...........................................  $ (95,683)         $ (36,743)         $ (37,169)         $ (24,809)
                                                              ==========         ==========         ==========         ==========
Per share data:
     Net loss...............................................  $    (.01)         $    (.00)         $    (.00)         $    (.00)
                                                              ==========         ==========         ==========         ==========

Common equivalent shares outstanding:                         17,170,390         15,693,797         17,170,390         16,138,467
                                                              ==========         ==========         ==========         ==========
</TABLE>
                                                 2

<PAGE>

<TABLE>

                        ALLERGY IMMUNO TECHNOLOGIES, INC.

                            BALANCE SHEET (UNAUDITED)

<CAPTION>


                                                                         November 30,
                                                                             1999
                                                                         ------------
<S>                                                                      <C>
Assets


Current Assets
    Cash .............................................................   $       0
    Accounts receivable, less allowance for doubtful accounts.........       9,765
    Inventory.........................................................       6,456
    Prepaid expenses and other current assets.........................       2,072
                                                                         ----------
          Total Current Assets .......................................      18,293

Land held for investment..............................................      46,000

Fixed assets, net of accumulated depreciation.........................       1,496

Patents, net of accumulated amortization..............................      12,384
                                                                         ----------

Total assets..........................................................   $  78,173
                                                                         ==========
</TABLE>


The accompanying notes are an integral part of these statements


                                       3


<PAGE>
<TABLE>


                        ALLERGY IMMUNO TECHNOLOGIES, INC.

                            BALANCE SHEET (UNAUDITED)

<CAPTION>

                                                                                  November 30,
                                                                                      1999
                                                                                 -------------
<S>                                                                              <C>
Liabilities and Shareholders' Deficit

Current Liabilities



     Accounts payable and accrued expenses...................................... $      7,146
     Due to affiliate...........................................................      198,386
                                                                                 -------------
          Total Current Liabilities.............................................      205,532


Shareholders' Deficit

     Common stock, $.001 par value authorized 50,000,000 shares,
       issued and outstanding 17,170,390  ......................................       17,170
     Additional paid-in-capital.................................................    1,777,388
     Accumulated deficit........................................................   (1,921,917)
                                                                                 -------------
Total Shareholders' Deficit.....................................................     (127,359)
                                                                                 -------------
Total Liabilities and Deficit................................................... $     78,173
                                                                                 =============
</TABLE>

The accompanying notes are an integral part of these statements.


                                       4

<PAGE>
<TABLE>

                                               ALLERGY IMMUNO TECHNOLOGIES, INC.

                                             STATEMENTS OF CASH FLOWS (UNAUDITED)
<CAPTION>

                                                                                    SIX MONTHS ENDED NOVEMBER 30
                                                                                   1999                      1998
                                                                               ------------              ------------
<S>                                                                            <C>                       <C>
Cash flows from operating activities:


Net loss .................................................................     $   (95,683)              $   (36,743)



Adjustments to reconcile net loss to net cash provided by
  (used in) operating activities:
     Depreciation and amortization........................................           1,326                     1,429
     Changes in current assets and liabilities:
       Accounts Receivable................................................           3,785                    13,144
       Inventory..........................................................               0                    (1,012)
       Prepaid expenses and other current assets..........................           1,207                       498
       Accounts payable and other accrued liabilities.....................            (573)                    8,445
       Other receivable-consulting........................................         100,000                         0
                                                                               ------------              ------------
Net cash provided by (used in) operating activities.......................          10,062                   (14,239)
                                                                               ------------              ------------
Cash flows provided by (used in) investing activities:
     Purchases of property and equipment..................................          (2,642)                        0
Net cash provided by (used in) investing activities.......................          (2,642)                        0
                                                                               ------------              ------------

    Advances from affiliate...............................................          (9,622)                   14,001
                                                                               ------------              ------------
Net cash (used in) provided by financing activities.......................          (9,622)                   14,001
                                                                               ------------              ------------
Net change in cash .......................................................          (2,202)                     (238)
                                                                               ------------              ------------
Cash at beginning of year.................................................           2,202                     3,562
                                                                               ------------              ------------
Cash at end of quarter....................................................     $         0               $     3,324
                                                                               ============              ============
</TABLE>

The accompanying notes are an integral part of these statements.

                                       5

<PAGE>

<TABLE>

                        ALLERGY IMMUNO TECHNOLOGIES, INC.

            STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT (UNAUDITED)

                   FOR THE SIX MONTHS ENDED NOVEMBER 30, 1999

<CAPTION>



                                      Common Stock
                                 ------------------------        Additional      Accumu-
                                 Number of                       Paid-In          Lated
                                 Shares           Amount         Capital         (Deficit)          Total
                                 ------           ------         -------         ---------          -----
<S>                              <C>              <C>            <C>             <C>             <C>
Balance at
  May 31, 1999                   17,170,390       $17,170        $1,777,388      $(1,826,234)    $ (31,676)

Net loss                                                                             (95,683)      (95,683)
                                 ----------       -------        ----------      ------------    ----------
Balance at
  November 30, 1999              17,170,390       $17,170        $1,777,388      $(1,921,917)    $(127,359)
                                 ==========       =======        ==========      ============    ==========

</TABLE>




The accompanying notes are an integral part of these statements.


                                       6

<PAGE>


                          NOTES TO FINANCIAL STATEMENTS


November 30, 1999

(1)    Reference is made to Note 1 of the Notes to Financial Statements
       contained in the Company's Annual Report on Form 10-KSB for the fiscal
       year ended May 31, 1999, for a summary of significant accounting policies
       utilized by the Company.

(2)    The information set forth in these statements is unaudited. The
       information reflects all adjustments which, in the opinion of management,
       are necessary to present a fair statement of results of operations of
       Allergy Immuno Technologies, Inc., for the periods indicated. It does not
       include all information and footnotes necessary for a fair presentation
       of financial position, results of operations, and cash flow in conformity
       with generally accepted accounting principles.

(3)    Results of operations for the interim periods covered by this Report may
       not necessarily be indicative of results of operations for the full
       fiscal year.

(4)    Earnings Per Share
       ------------------

       In February 1997, the Financial Accounting Standards Board ("FASB")
       issued Statement of Financial Accounting Standards (SFAS) No. 128,
       EARNINGS PER SHARE ("EPS"). SFAS No. 128 requires dual presentation of
       basic EPS and diluted EPS on the face of all income statements issued
       after December 15, 1997 for all entities with complex capital structures.
       Basic EPS is computed as net income divided by the weighted average
       number of common shares outstanding for the period. Diluted EPS reflects
       the potential dilution that could occur from common shares issuable
       through stock options, warrants and other convertible securities.

       The following table illustrates the required disclosure of the
       reconciliation of the numerators and denominators of the basic and
       diluted EPS computations:

                                       7

<PAGE>

<TABLE>

                                                             For the Six Months Ended November 30, 1999
                                                             ------------------------------------------
                                                                Income         Shares        Per Share
                                                             (Numerator)    (Denominator)      Amount
                                                            -------------   -------------   -------------
<S>                                                         <C>               <C>               <C>
Basic EPS -
     Loss available to common
      Shareholders..................................        $    (95,683)     17,170,390           ($.00)
                                                                                            =============

Effect of dilutive securities - Options.............                 -             -
                                                            -------------   -------------
Diluted EPS -
     Loss available to common share-
      Holders plus assumed conversions..............        $    (95,683)     17,170,390           ($.00)
                                                            =============   =============   =============


<CAPTION>

                                                             For the Six Months Ended November 30, 1998
                                                             ------------------------------------------
                                                                Income         Shares        Per Share
                                                             (Numerator)    (Denominator)      Amount
                                                            -------------   -------------   -------------
<S>                                                         <C>               <C>               <C>

Basic EPS -
     Loss available to common
      Shareholders..................................        $    (36,743)     15,693,797           ($.00)
                                                                                            =============
Effect of dilutive securities - Options.............                 -
                                                            -------------   -------------
Diluted EPS -
     Loss available to common share-
      Holders plus assumed conversions..............        $    (36,743)     15,693,797           ($.00)
                                                            =============   =============   =============


                                                             For the Three Months Ended November 30, 1999
                                                             --------------------------------------------
                                                                Income         Shares        Per Share
                                                             (Numerator)    (Denominator)      Amount
                                                            -------------   -------------   -------------
<S>                                                         <C>               <C>               <C>
Basic EPS -
     Loss available to common
      Shareholders..................................        $    (37,169)     17,170,390           ($.00)
                                                                                            =============
Effect of dilutive securities - Options.............                 -             -
                                                            -------------   -------------
Diluted EPS -
     Loss available to common share-
      Holders plus assumed conversions..............        $    (37,169)     17,170,390           ($.00)
                                                            =============   =============   =============


                                       8

<PAGE>

                                                             For the Three Months Ended November 30, 1998
                                                             ---------------------------------------------
                                                                Income         Shares        Per Share
                                                             (Numerator)    (Denominator)      Amount
                                                            -------------   -------------   -------------
<S>                                                         <C>               <C>               <C>

Basic EPS -
     Loss available to common
      Shareholders..................................        $    (24,809)     16,138,467           ($.00)
                                                                                            =============
Effect of dilutive securities - Options.............                 -
                                                            -------------   -------------
Diluted EPS -
     Loss available to common share-
      Holders plus assumed conversions..............        $    (24,809)     16,138,467           ($.00)
                                                            =============   =============   =============
</TABLE>


5.   The Company currently operates a Novell-based LAN system put in place in
     November 1994. The Company's computers have been upgraded to year 2000
     compliant equipment. The Company shares accounting software with Biomerica
     and the software was upgraded in March of 1999. The cost of these upgrades
     was not material. The accounting and record-keeping software that is
     employed at AIT is in wide use.

     The Company does not place orders electronically nor does it make
     disbursements to vendors or employees in that medium. The Company has a
     broad base of available suppliers and therefore is not heavily reliant on
     any one supplier outside of the Company. The Company has a limited number
     of customers and the impact, if any, of Year 2000 related problems on the
     Company's customers could have an adverse affect on the Company.

     As of January 11, 2000 the Company has not experienced any Year 2000
     related problems internally and is not aware of any Year 2000 problems with
     vendors, customers, other business associates or with Internet functions.
     However, the Company has no way of knowing whether there will be any future
     problems related to the Year 2000 issue and cannot guarantee that these
     would not have an adverse affect on the Company.



                                       9



<PAGE>


                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                 FINANCIAL CONDITION AND SELECTED FINANCIAL DATA


       THE STATEMENTS IN THIS REPORT ON FORM 10-QSB AND OTHER STATEMENTS MADE BY
ALLERGY IMMUNO TECHNOLOGIES, INC. THAT RELATE TO FUTURE PLANS, EVENTS OR
PERFORMANCE ARE FORWARD-LOOKING STATEMENTS WHICH INVOLVE RISKS AND
UNCERTAINTIES. ACTUAL RESULTS, EVENTS OR PERFORMANCE MAY DIFFER MATERIALLY FROM
THOSE ANTICIPATED IN ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF A VARIETY OF
FACTORS, INCLUDING, BUT NOT LIMITED TO, COMPETITION, WHICH HAS AND WILL CONTINUE
TO PUT PRICE PRESSURE ON THE COMPANY'S THIRD PARTY COLLECTION RECEIVABLES, AND
OVERALL MACRO-ECONOMIC CONDITIONS.



RESULTS OF OPERATIONS

     Net sales for Allergy Immuno Technologies were $43,591 for the six months
ended November 30, 1999 as compared to $38,195 for the same period in the
previous year. This represents an increase of $5,396, or 14%. For the three
months then ended sales were $18,692 as compared to $15,048 in fiscal 1999. This
represents an increase of $3,644, or 24%. The six and three-month sales
increases were due to sales to several new accounts, which the Company did not
have in the previous fiscal year. Cost of sales for the six months decreased
from $42,790 to $42,057, or $733, or 2%. The Company had a gross profit of 3.5%
of sales as compared to a gross loss of 12.0% of sales for the six month period
in fiscal 2000 compared to fiscal 1999. The improvement in gross margin was due
to lower material costs as a percentage of sales, higher sales and fixed costs
remaining close to the previous year's. Cost of sales for the quarter ended
November 30, 1999 decreased from $22,995 to $18,884, or $4,111 (18%). The
decrease in cost of sales was primarily due to lower material and wage costs in
fiscal 2000. For the three- month period, the gross loss decreased from 52.8% of
sales to 1% of sales. This decrease was primarily due to higher sales in
addition to lower material and wage costs.

    Selling, general and administrative costs for the six months ended November
30, increased from $31,931 in fiscal 1999 to $97,011 in fiscal 2000. This
represents an increase of $65,080 (204%). For the quarter then ended selling,
general and administrative costs increased from $17,551 to $37,307, or $19,756
(113%). Much of the increase was due to an increase in legal and accounting
costs associated with the filing of the Company's Form 10-SB and Form 10-KSB. In
the prior fiscal year these forms were not required to be filed by the Company
and therefore it did not incur such costs. The Company will be incurring more
legal and accounting costs on an on-going basis than previously due to
government filing requirements. The initial filing, Form 10-SB, is a
non-recurring filing requirement, however, other reports will be required, such
as this Form 10-QSB. In addition, the Company had higher payroll and related
costs associated with business development.

     During the first quarter the Company received a payment of $100,000 (which
was recorded as income in the prior fiscal year) for consulting services and an
option to purchase 10,000 Class A Units of Hollister-Stier LLC at a purchase
price of $10 per unit.

LIQUIDITY AND CAPITAL RESOURCES

     As of November 30, 1999, the Company had a zero cash balance as compared to
$3,324 in the previous year. Its current working capital deficit is $187,239 as
compared to a deficit of $145,287 for the previous year.

                                       10

<PAGE>

     The Company has been experiencing losses and has had to rely on borrowings
from Biomerica, Inc., which owns approximately 74.6% of the outstanding stock of
AIT. Management believes that losses will continue during this fiscal year.
Biomerica has agreed to provide continued financial and management support, if
necessary, at least through the end of this fiscal year. As of November 30, 1999
the Company owed Biomerica $198,386. Biomerica is not charging the Company
interest on the advances and has not determined any date of repayment. In the
past Biomerica has taken the Company's stock as repayment for cash advanced.




                                       11



<PAGE>


                           PART II. OTHER INFORMATION


Item 1.     LEGAL PROCEEDINGS.  Inapplicable.

Item 2.     CHANGES IN SECURITIES.  Inapplicable.

Item 3.     DEFAULTS UPON SENIOR SECURITIES.  Inapplicable.

Item 4.     SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.  Inapplicable.

Item 5.     OTHER INFORMATION.  Inapplicable.

Item 6.     EXHIBITS AND REPORTS ON FORM 8-K.  None.






                                   SIGNATURES




Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has fully caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

Date:  January 5, 2000




                                          ALLERGY IMMUNO TECHNOLOGIES, INC.


                                          By: /S/ Zackary S. Irani
                                              ------------------------------
                                              Zackary Irani,
                                              President, Chief Executive Officer





                                       12